Britain | EUROPESAYS.COM
  • /
  • Europe
  • France
  • Spain
  • Canada
  • Australia
  • Africa
  • Football
  • Tennis
  • Golf
  • PM
  • England
    • London
    • Cambridgeshire
    • Cumbria
    • Derbyshire
    • Devon
    • Dorset
    • East Sussex
    • Essex
    • Gloucestershire
    • Hampshire
    • Hertfordshire
  • Britain
  • …
    • Germany
    • Italy
    • Ukraine
    • Poland
    • Netherlands
    • Russia
    • Iran
    • Japan
    • AI
  • @
  • AstraZeneca
  • BAE Systems
  • Barclays
  • BP
  • Britain
  • British American Tobacco
  • Compass Group
  • Diageo
  • Glencore
  • GSK
  • HSBC
  • Lloyds Banking Group
  • London
  • London Stock Exchange Group
  • National Grid
  • NatWest
  • Reckitt Benckiser
  • Rio Tinto
  • Rolls-Royce
  • Shell
  • Standard Chartered
  • UK
  • Unilever
Britain | EUROPESAYS.COM
  • /
  • Europe
  • France
  • Spain
  • Canada
  • Australia
  • Africa
  • Football
  • Tennis
  • Golf
  • PM
  • England
    • London
    • Cambridgeshire
    • Cumbria
    • Derbyshire
    • Devon
    • Dorset
    • East Sussex
    • Essex
    • Gloucestershire
    • Hampshire
    • Hertfordshire
  • Britain
  • …
    • Germany
    • Italy
    • Ukraine
    • Poland
    • Netherlands
    • Russia
    • Iran
    • Japan
    • AI
  • @

Browsing Tag

AIM

3 posts
LLondon Stock Exchange Group
Given no article content, categories, or tags, and a generic filename, I cannot generate a specific alt text. I need more ...
Read More

London Stock Exchange unveils ‘LSE24’ round-the-clock trading venue

  • July 21, 2026
Tuesday 21 July 2026 8:39 am The venue will be open 24 hours, 5 days a week The…
LLondon
Assura has been the subject of a ferocious bidding war for nearly six months
Read More

London-listed healthcare services firm hit by cyberattack

  • July 20, 2026
Monday 20 July 2026 8:22 am  |  Updated:  Monday 20 July 2026 8:38 am Edinburgh-based Craneware provides cost management…
AAstraZeneca
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Read More

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

  • June 8, 2026
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…
Britain | EUROPESAYS.COM
www.europesays.com